Am­ryt Phar­ma sub­mits a for­mal dis­pute res­o­lu­tion to the FDA over re­ject­ed skin dis­ease drug

The sto­ry of Am­ryt Phar­ma’s can­di­date for the ge­net­ic skin con­di­tion epi­der­mol­y­sis bul­losa, or EB, will soon en­ter an­oth­er chap­ter.

Af­ter the Irish drug­mak­er’s can­di­date …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER